{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037962","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.163677+00:00","generated_at":"2026-06-12T08:00:45.254208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ultragenyx Q2 2023 revenue $108.3M (+21% YoY); reaffirms 2023 guidance","bullets":["Q2 total revenue $108.3M vs $89.3M YoY; Crysvita $83.0M (+20%), Dojolvi $16.5M, Mepsevii $8.4M.","Net loss $159.8M ($2.25/sh) compared to $158.2M ($2.26) in Q2 2022; cash and equivalents $618.4M.","Reaffirmed FY2023 guidance: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.","Setrusumab Phase 2 OI data: 9.4% BMD increase at 20mg/kg in 3 months; Phase 3 Orbit/Cosmic enrolling.","Howard Horn appointed CFO and EVP Corporate Strategy effective Oct 16, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037962","json":"https://secwatch.observer/filing/0000950170-23-037962.json","markdown":"https://secwatch.observer/filing/0000950170-23-037962.md","text":"https://secwatch.observer/filing/0000950170-23-037962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/0000950170-23-037962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/rare-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:00:45.254208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ceea52a750e373e7764be77b4bce4ba36f5cec77","claim":"Ultragenyx Pharmaceutical Inc. reported the quarter ended June 30, 2023 results: revenue $108.3 million, net income net loss of $159.8 million, or $2.25 per share basic and diluted, EPS $2.25 per share basic and diluted. Guidance reaffirmed.","evidence_excerpt":"Mepsevii 8,439 4,933 16,919 9,794 Evkeeza 365 — 577 — Daiichi Sankyo — 1,479 1,479 4,728 Total revenues $ 108,309 $ 89,343 $ 208,805 $ 169,278 Total Revenues Ultragenyx reported $108.3 million in total revenue for the second quarter of 2023, which represents 21% growth compared to the second quarter 2022. This includes second quarter 2023 Crysvita revenue in North","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023037962/0000950170-23-037962-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$108.3 million"},{"label":"Net income","value":"net loss of $159.8 million, or $2.25 per share basic and diluted"},{"label":"EPS","value":"$2.25 per share basic and diluted"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}